Nuclear receptor 4A2: a potential drug target for glioblastomas

Takeaway

  • Knockdown of the orphan nuclear receptor 4A2 (NR4A2) inhibits growth, cell death and invasion/migration of glioblastoma (GBM) cells in human derived cell lines, established cell lines and mice xenografts indicating its pro-oncogenic role and potential to be a target for drug development.

Why this matters

    Three-year survival rates for people with GBM are low, and new therapies are urgently needed. Antagonists of NR4A2 offer potential promise as new therapeutic agents for people with GBM expressing this receptor.